tbuckley/cabot-search huggingface dataset:
FRI-068-Quantitative biliary tree imaging by MRI: Evaluating new technology across patient cohorts with autoimmune liver disease
Authors: Katherine Arndtz, James Hodson, Peter Eddowes, Gary Woodward, Marija Mavar, Ged Ridgway, Carlos Ferreira, Andrea Borghetto, Matt Kelly, John Michael Brady, Rajarshi Banerjee, Gideon Hirschfield
Journal: Journal of Hepatology (2019)
Maternal triacylglycerol signature and risk of food allergy in offspring
Authors: Xiumei Hong, Liming Liang, Qi Sun, Corinne A. Keet, Hui-Ju Tsai, Yuelong Ji, Guoying Wang, Hongkai Ji, Clary Clish, Colleen Pearson, You Wang, Robert A. Wood, Frank B. Hu, Xiaobin Wang
Journal: Journal of Allergy and Clinical Immunology (2019)
Stereotactic radiotherapy concurrent to immune or targeted therapy for oligometastatic NSCLC: Clinical scenarios affecting survival
Authors: S.G.C. Kroeze, C. Fritz, D. Kaul, O. Blanck, K. Kahl, F. Roeder, S. Siva, J.J.C. Verhoeff, A.L. Grosu, M.M. Schymalla, M. Glatzer, M. Szuecs, M. Geier, G. Skazikis, I. Sackerer, F. Lohaus, F. Eckert, M. Guckenberger
Journal: Annals of Oncology (2019)

Background: Oligometastatic NSCLC pts. may benefit from a more aggressive treatment approach. However, the concept of "oligometastasis" is complex: e.g. limited progression or resistance of disease to systemic treatment. This study evaluated the outcome of stereotactic radiotherapy (SRT) to oligoprogressive or oligoresistant NSCLC in pts. receiving concurrent immuno- or targeted therapy. Methods: The international register study (TOaSTT) collected data on metastatic NSCLC pts. receiving SRT concurrent (≤30d) to immuno- or targeted therapy. Pts. were grouped in: SRT of ≤ 5 metastases without additional metastases (oligoprogression), SRT of ≤ 5 progressive metastases with controlled disease of all other metastases (oligopersistent), and SRT of ≤ 5 metastases with otherwise mixed response/ uncontrolled disease. OS, PFS, LC and time to systemic therapy-switch after SRT were analyzed using Kaplan-Meier survival curves and log rank testing. Toxicity was scored using CTCAE. Results: SRT of 192 lesions in 108 pts. was performed between 7/2009 - 5/2018. Median age was 63y (range 33-80). Driver mutations were: EGFR 41%, ALK 14%, other 21%, unknown/no 24%. Median FU was 18.7 (range 1-102) mo. 90% were ECOG 0-1. Median 1 (range 1-5) metastasis was treated. Targeted therapies were started before SRT in 69%, during SRT in 8%, and after SRT in 23%. 60% received an ALK- or EGFR-TKI, 31% PD-L1/PD-1 inhibitors, 8% bevacizumab. Oligoprogressive and oligopersistent pts showed improved OS compared to advanced metastatic disease (p = 0.008) (Fig.1). PFS was best in oligoprogressive patients; median 20.1 vs 7 and 4.4 mo. (p = 0.006). LC was median 21.0, 12.0 und 9.0mo: no sign. difference between groups. After 1y, 86%, 47% and 39% continued the same immuno- or targeted therapy as before SRT. Severe acute toxicity were observed in 7%, late toxicity in 4%. Conclusions: An excellent survival with limited toxicity was observed when definitive SRT to a limited number of metastases was combined with targeted- or immunotherapy in oligoprogressive and oligopersistent NSCLC patients. SRT of metastatic sites allowed continuation of targeted-, or immunotherapy in many patients. These observations need to be further evaluated in prospective trials. Legal entity responsible for the study: Matthias Guckenberger. Funding: Has not received any funding. Disclosure: All authors have declared no conflicts of interest.
SAT-238-The impact of SVR from direct acting antiviral and interferon-based treatments for HCV on hepatocellular carcinoma risk in a large population based cohort
Authors: Naveed Janjua, Stanley Wong, Carmine Rossi, Maryam Darvishian, Amanda Yu, Zahid A Butt, Eric Yoshida, Alnoor Ramji, Jordan Feld, Mawuena Binka, Sofia Bartlett, Dr. Margo Pearce, Maria Alvarez, Hasina Samji, Mark Tyndall, Mel Krajden
Journal: Journal of Hepatology (2019)
What Readmission Rates in Canada Tell Us About the Hospital Readmissions Reduction Program
Authors: Ashish K. Jha
Journal: JAMA Cardiology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
Abstract 17564: Hemodynamic Response to Continuous-Flow Left Ventricular Assist Device Ramp Test and Volume Loading Predicts Successful Weaning From the Device Support
Authors: Shunsuke Saito, Koichi Toda, Shigeru Miyagawa, Yasushi Yoshikawa, Hiroki Hata, Tetsuya Saito, Keitaro Domae, Noriyuki Kashiyama, Yasushi Sakata, Yoshiki Sawa
Journal: Circulation (2017)

Introduction: Myocardial recovery occurs in small cohort of patients receiving left ventricular assist device (LVAD) support, but identification of candidates for device removal remains challenging. Hypothesis: We hypothesized that hemodynamic evaluation during LVAD speed ramp and volume loading test can assess cardiac recovery to predict successful device removal. Methods: The LVAD pump speed was decreased in 4 stages from the patient’s optimal speed to the minimal setting of the device. Under the minimal LVAD support, saline loading (body weight x 10mL in 15 minutes) was done. Echocardiographic and right heart catheter data were obtained in each stage of the LVAD ramp test, and every 3 minutes during the saline loading test. A total of 31 patients (HeartMate II 12, DuraHeart 7, Jarvik2000 5, EVAHEART 5, HVAD 2) underwent the test at our institution. The patients were divided into 2 groups: those who underwent successful LVAD explantation (Group R, n = 6) and those who did not (Group N, n = 25). Echocard...
FRI-188-Sequence analysis of baseline and on-treatment samples from HBV-infected chronic hepatitis B patients treated for 28 days with JNJ-56136379 monotherapy
Authors: Thierry Verbinnen, Moana Hodari, Willem Talloen, Jan Martin Berke, David Blue, Jeysen Yogaratnam, Umesh Shukla, Sandra De Meyer, Oliver Lenz
Journal: Journal of Hepatology (2019)
Molecular signature characterisation of different inflammatory phenotypes of systemic juvenile idiopathic arthritis
Authors: Faekah Gohar, Angela McArdle, Melissa Jones, Niamh Callan, Belinda Hernandez, Christoph Kessel, Maria Miranda-Garcia, Miha Lavric, Dirk Holzinger, Carolin Pretzer, Elke Lainka, Sebastiaan J Vastert, Sytze de Roock, Oliver FitzGerald, Stephen R Pennington, Dirk Foell
Journal: Annals of the Rheumatic Diseases (2019)

Objectives The International League of Associations for Rheumatology classification criteria define systemic juvenile idiopathic arthritis (SJIA) by the presence of fever, rash and chronic arthritis. Recent initiatives to revise current criteria recognise that a lack of arthritis complicates making the diagnosis early, while later a subgroup of patients develops aggressive joint disease. The proposed biphasic model of SJIA also implies a ‘window of opportunity’ to abrogate the development of chronic arthritis. We aimed to identify novel SJIA biomarkers during different disease phases. Methods Children with active SJIA were subgrouped clinically as systemic autoinflammatory disease with fever (SJIA syst ) or polyarticular disease (SJIA poly ). A discovery cohort of n=10 patients per SJIA group, plus n=10 with infection, was subjected to unbiased label-free liquid chromatography mass spectrometry (LC-MS/MS) and immunoassay screens. In a separate verification cohort (SJIA syst , n=45; SJIA poly , n=29; infection, n=32), candidate biomarkers were measured by multiple reaction monitoring MS (MRM-MS) and targeted immunoassays. Results Signatures differentiating the two phenotypes of SJIA could be identified. LC-MS/MS in the discovery cohort differentiated SJIA syst from SJIA poly well, but less effectively from infection. Targeted MRM verified the discovery data and, combined with targeted immunoassays, correctly identified 91% (SJIA syst vs SJIA poly ) and 77% (SJIA syst vs infection) of all cases. Conclusions Molecular signatures differentiating two phenotypes of SJIA were identified suggesting shifts in underlying immunological processes in this biphasic disease. Biomarker signatures separating SJIA in its initial autoinflammatory phase from the main differential diagnosis (ie, infection) could aid early-stage diagnostic decisions, while markers of a phenotype switch could inform treat-to-target strategies.
Circular RNA MAT2B Promotes Glycolysis and Malignancy of Hepatocellular Carcinoma Through the miR‐338‐3p/PKM2 Axis Under Hypoxic Stress
Authors: Qing Li, Xiongxiong Pan, Deming Zhu, Zhengming Deng, Runqiu Jiang, Xuehao Wang
Journal: Hepatology (2019)

Glucose metabolism reprogramming, which is a well-established characteristic of multiple cancers, demands a higher rate of glycolysis to meet the increasing demands for macromolecular synthesis and to maintain rapid proliferation in a hypoxic environment. However, the mechanism underlying this switch remains to be elucidated. In this study, we investigated the function of circular RNA MAT2B (circMAT2B) in hepatocellular carcinoma (HCC) glucose metabolism reprogramming and malignancy. CircMAT2B was identified by bioinformatics analysis of Gene Expression Omnibus data sets. CircMAT2B expression was up-regulated in HCC tissues and cell lines. HCC patients with high circMAT2B expression had shortened overall survival. We analyzed the positive correlation between glycolysis and circMAT2B expression in HCC using a maximum standardized uptake value determined by preoperative positron emission tomography/computed tomography scanning combined with high-performance liquid chromatography assessment of the metabolites of glycolysis and the citric acid cycle. The effect of circMAT2B on glycolysis was validated in vitro and in vivo under hypoxic (1% O2 ) conditions. Functional assays were performed in HCC cells, HCC organoids, and nude mice to explore the tumor-promoting roles of circMAT2B in HCC. Biotin-coupled probe pull-down assays, biotin-coupled microRNA capture, luciferase reporter assays, fluorescence in situ hybridization, and RNA immunoprecipitation assays were performed to confirm the interaction among different RNAs. Mechanistically, we demonstrated that circMAT2B up-regulated expression levels of the microRNA (miR)-338-3p target gene PKM2, which encodes a key enzyme in the process of glycolysis, through "sponging" miR-338-3p; thus, glycolysis and HCC progression are promoted through this mechanism. Conclusion: CircMAT2B promoted HCC progression by enhanced glycolysis by activating the circMAT2B/miR-338-3p/PKM2 axis under hypoxia, which may provide a therapeutic target for HCC.
A phase II trial of sorafenib (SO) in advanced chordoma patients (pt).
Authors: Eric Amela, Emmanuelle Bompas, Axel Le Cesne, Emmanuelle Tresch, Antoine Italiano, Sophie Piperno-Neumann, Olivier Collard, Damien Vansteene, Julien Domont, Esma Saada, Nicolas Isambert, Sebastien Salas, Christine Chevreau, Francois Bertucci, Stephanie CLISANT DELAINE, Jean-Yves Blay, Nicolas Penel
Journal: Journal of Clinical Oncology (2015)

10520 Background: To report in a hypothesis-generating phase II study the activity and safety of SO in advanced chordomas. Methods: Pts received SO 800 mg/d until progression, intolerance or up to 9 months (mo) and intolerance. The primary endpoint was progression-free survival according to RECIST 1.1. Secondary end-points were RR, OS and toxicity. Results: From 07/2011 to 01/2014, 27 pts were enrolled (median age 64, range 30-86), including 17 men and 10 women. The primary tumor locations were sacrum (21, 77.7%), rachis (4, 14.8%) and clivus (3, 11.1%). Metastasis was present in 14 pts (58.3%). Twenty-six pts (96.3%) had received prior treatment, including surgery (18, 66.7%), radiotherapy (18, 66.7%) and prior systemic therapies (MTT; 12, 44.4%; median number of lines 1, range 1-3). The duration of SO treatment was 4.9 months (range, 0.5-10.1). The median relative dose-intensity was 1 (range, 0.43-1). Because of toxicity, treatment was temporarily discontinued for 11 pts (40.7%) and dose-reduction was necessary in 10 cases (37.0%) A 6 mo, we have observed 1 delayed RECIST-based partial response confirmed at 9 mo. The median follow-up was 8.7 mo (1.2-31.0 mo). The 12 month-PFS rate was 57.4% (95CI 34.7-74.7) in the whole population, and 63.6% (32.7-83.3) and 47.1% (15.2-74.1) in pts naïve to and those previously treated by MTT, respectively. The 12 month-OS rate was 86.5% (55.8-96.5). Three (11.1%) and 14 (51.8%) pts experienced grade (Gr) 4 and Gr 3 toxicities. The Gr 4 toxicities were thyrotoxicosis (1 case), skin toxicity (1 case) and arterial hypertension (1 case). The most common Gr 3 toxicities were arterial hypertension (5), skin toxicity (5) and diarrhea (5, 18.5%). One keratoacanthoma occurred during follow-up. Conclusions: This trial showed a promising activity of SO in advanced chordoma. Further clinical explorations (e.g. randomization trial with discontinuation design) are warranted. Clinical trial information: 2009-017020-59.
SAT-493-Prevalence and clinical significance of intrahepatic cholangiocellular carcinoma with radiological enhancement pattern mimicking hepatocellular carcinoma
Authors: Luca Vigano, Ana Lleo, Riccardo Muglia, Nicolo Gennaro, Laura Sama, Francesca Colapietro, Luca Di Tommaso, Alessio Aghemo, Massimo Roncalli, Luigi Solbiati, massimo colombo, Guido Torzilli
Journal: Journal of Hepatology (2019)
Activity and safety of trabectedin in patients with sarcomatoid / biphasic malignant pleural mesothelioma (MPM).
Authors: Diego Luigi Cortinovis, Lital Hannah Hollander, Irene Claudia Floriani, Federica Grosso, Alessandro Marinello, Giovanni Luca Ceresoli, Ilaria Pacchetti, Paolo Andrea Zucali, Maurizio D'Incalci, Stefania Canova, Maria Ida Abbate, Francesca Ugo, Suela Vukcaj, Paolo Bidoli
Journal: Journal of Clinical Oncology (2015)

7561 Background: The efficacy of available MPM therapies is poor in patients (pts) with sarcomatoid/biphasic histotypes , and their prognosis remains dismal. The use of Trabectedin (T) in MPM is justified by its peculiar mechanism of action, involving modulation of the tumor’s inflammatory microenvironment, and the demonstrated activity against a range of tumours, including sarcomas. We aimed to study the activity and safety of T in pts with both epithelioid and biphasic/sarcomatoid MPM. Methods: ATREUS, an Italian multicenter single arm phase II trial, evaluates T as second line therapy in pts with epithelioid histotype and as first/second line in biphasic/sarcomatoid pts. In the latter cohort, the study needed to enroll 17 evaluable pts to reject with a 10% one sided alpha error the null hypothesis that 12-week progression free survival (12w PFS) is ≤ 15% and an 85% power to show 12w PFS in ≥ 40% of pts. Overall survival and safety were secondary endpoints. Pts were treated with T, 1.3 mg/m2, over 3 hours every 21 days, until progression or unacceptable toxicity. Results: The cohort of sarcomatoid/biphasic pts is now complete and results are reported below. Twenty three pts were enrolled and 17 were evaluable (14 M and 3 F, median age 67.9 years). Ten, six and one pts had stage IV, III and II disease, respectively. Seven (41.2%) were treatment naïve. At 12 weeks 7/17 pts (41.2%, 95% CI: 18.4-67.1) were alive and free of progression. Five patients (29.4%) had sustained response with PFS ≥ 18 weeks. By the time of analysis all pts interrupted treatment. Interruption reasons were disease progression in 12 pts, death (4 pts) and consent withdrawal in one pt. The most frequent grade ≥ 3 treatment related toxicities were non febrile neutropenia (11.8%), nausea (17.6%), vomiting, mucositis and fever/infection (each observed in one patient, 5.9%). Two serious adverse events , classified as possibly related to T, occurred. One was fatal. Conclusions: T demonstrated its activity in terms of PFS and was well tolerated in this population of patients with advanced sarcomatoid/biphasic MPM. These optimistic results merit to be further investigated in a larger sample. Clinical trial information: NCT02194231.
Occupational Vision Loss Following Alexandrite Laser Exposure
Authors: Dimitrios Karagiannis, Maria Stoupaki, George A. Kontadakis
Journal: JAMA Dermatology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Abstract 17393: Markers of Cholesterol Metabolism Predict Cardiovascular Events
Authors: Oliver Weingärtner, Dieter Lütjohann, Bodo Cremers, Sarah Seiler-Mußler, Hans F Schött, Anja Anja, Silvia Friedrichs, Sven Meyer, Ursula Ulbricht, Adam Zawada, Ulrich Laufs, Bruno Scheller, Danilo Fliser, Michael Böhm, Gunnar H Heine
Journal: Circulation (2017)

Aims: We aimed to prospectively analyze the association of serum surrogate markers of cholesterol homeostasis with future cardiovascular events in a population admitted for coronary angiography. Me...
Abstract #2793: MEDI3617, a fully human anti-angiopoietin 2 monoclonal antibody, demonstrates efficacy and tolerability alone and in combination with chemotherapy in xenograft models.
Authors: Ching Ching Leow, Christine Fazenbaker, Karen Coffman, Shannon Ready, Mohammad Tabrizi, William Dall'Acqua, Bahija Jallal, Yong Chang, Steve Coats
Journal: Cancer Research (2009)

Angiopoietin 2 (Ang2) is an important regulator of angiogenesis, blood vessel maturation and integrity of the vascular endothelium. Ang2-Tie2 interactions for vascular remodeling have been shown to play an important role in tumor vessel plasticity. We have developed MEDI3617, a fully human IgG1 anti-Ang2 monoclonal antibody with binding affinity (Kd) to human Ang2 of 40pM. In vitro, MEDI3617 effectively blocked Ang2 from binding to Tie2 in a competition ELISA assay (IC50 = 1.34nM) and inhibited Ang2-mediated Tie2 phosphorylation in HEK-293/Tie2 stable cells (IC50 = 0.85nM). We have demonstrated in vivo, the anti-angiogenic acitivity of MEDI3617, through inhibition of neonatal retinal vasculogenesis and angiogenesis in tumor xenografts and matrigel plugs. We have also demonstrated single agent activity in multiple tumor types. In addition, we examined the potential of combining MEDI3617 with chemotherapeutic agents such as Xeloda and Taxol. For both Xeloda and Taxol, we observed tumor stasis in Colo205 (colorectal), and A375 (melanoma) xenograft models, respectively. MEDI3617 administered as a single agent at 10 mg/kg and 20 mg/kg resulted in tumor growth inhibition of approximately 60% in Colo205 and A375, respectively. When MEDI3617 was administered in combination with Xeloda in Colo205 or in combination with Taxol in A375 xenografts, significant tumor growth delay was achieved and no significant body weight loss was detected. These studies demonstrate that MEDI3617 has anti-angiogenic activity resulting in inhibition of tumor as single agent and in combination with chemotherapy.  Citation Information: In: Proc Am Assoc Cancer Res; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr 2793.
The therapeutic benefit and toxicity from multiple myeloma phase I trials, 2004 through 2014.
Authors: Ehsan Malek, James J Driscoll, Jeffrey Welge
Journal: Journal of Clinical Oncology (2015)

8585 Background: Despite the therapeutic benefit of novel agents, majority of multiple myeloma (MM) patients inevitably relapse leading to poor clinical outcomes. During the past decade, there has been an unprecedented pace of new anti-myeloma compound discovery tested through phase I trials, mostly in relapse/refractory setting. In the same period of time, at least 9 agents have been FDA approved for relapse MM that makes the decision making between standard therapy vs. recruitment on phase I trial poorly defined and occasionally ethically challenged. Further, the current perception of low therapeutic benefit from participation in phase I trials is the main obstacle for patient recruitment and make the phase I trial as a “last resort” in overall therapeutic plan. Here, we present a global assessment of therapeutic benefit and toxicity of all MM phase I studies over the past decade that may lead to optimal timing of patients recruitment on phase I trials. Methods: We reviewed 43 phase I trials from 2004 until 2014 in a systematic fashion. Quality and rate of response, adverse effects and mortality from single agents as well as combination of the experimental agents with immunomodulators (IMiDs) and proteasome inhibitors (PIs) are reported. Results: 41 trials with total of 946 participants were analyzed. 21 were single agents and the reminder tested a combined regimens. Overall response rate (ORR), i.e., partial response or better, was observed in 34% of all patients, 16% with single agents and 42% with combination therapy. Patients participated in trials with combination therapies had more grade III-IV toxicity than single agents (HR: 1.35, p-value: 0.04). There were only 5 patients (less than 1% of all participants) who have therapy-related death. Single agents with anti-CD38 agent, daratumumab and oral PI, ixazomib, had the best single agent response rate, 45% and 36%, respectively. Conclusions: Median ORR from MM phase I trials even with single agents is higher than reported response rate from classic chemotherapy phase I trials (i.e. 5%), therefore phase I participation should not count as the “last resort” and MM patients should be offered the opportunity to participate in these trial at any stage after failure on IMiDs and PIs.
Characterization and Trajectory of Coronary Artery Calcium Percentiles: The Dallas Heart Study
Authors: Micah T. Eades, Andre R.M. Paixao, Anurag Mehta, Colby R. Ayers, Parag H. Joshi, Jarett D. Berry, James A. de Lemos, Amit Khera
Journal: JACC. Cardiovascular imaging (2019)